Mesoblast (NASDAQ:MESO) Shares Cross Below 50 Day Moving Average – Time to Sell?

Shares of Mesoblast Limited (NASDAQ:MESO) crossed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $16.09 and traded as low as $15.21. Mesoblast shares last traded at $15.29, with a volume of 451,398 shares traded.

Trending Headlines about Mesoblast

Here are the key news stories impacting Mesoblast this week:

• Positive Sentiment: The FDA clearance should support Mesoblast’s ability to release and monitor commercial Ryoncil batches, reducing a potential manufacturing and regulatory hurdle. The announcement initially helped MESO trade higher in premarket activity. Mesoblast Receives FDA Approval for New Potency Assay
• Neutral Sentiment: The regulatory decision concerns the testing method used to release and monitor Ryoncil, rather than a new indication or expansion of the product’s approved use. Investors may therefore view it as an operational milestone with limited immediate revenue impact. Mesoblast Gets FDA Approval for New Ryoncil Potency Assay
• Neutral Sentiment: A report stating that short interest totaled zero shares implies no measurable short-selling pressure, but the figure conflicts with the description of a “large increase” and may reflect incomplete or unreliable data. Mesoblast Secures US FDA Approval for New Potency Assay
• Negative Sentiment: Despite the FDA announcement, MESO came under pressure and was reported below its 50-day moving average. This suggests some investors may have taken profits or considered the approval already priced in, creating a negative technical signal in the near term. Mesoblast Shares Cross Below 50 Day Moving Average

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a research report on Thursday. Piper Sandler reiterated an “overweight” rating and set a $39.00 target price (up from $35.00) on shares of Mesoblast in a report on Thursday, August 27th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Mesoblast in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Mesoblast presently has a consensus rating of “Hold” and a consensus price target of $39.00.

Mesoblast Stock Down 2.3%

The company has a current ratio of 2.43, a quick ratio of 2.09 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $1.96 billion, a P/E ratio of -54.00 and a beta of 2.12. The firm’s 50 day moving average price is $15.99 and its two-hundred day moving average price is $15.31.

Mesoblast (NASDAQ:MESO) last announced its quarterly earnings data on Friday, July 31st. The company reported ($0.07) EPS for the quarter. The firm had revenue of $34.45 million for the quarter. Equities research analysts forecast that Mesoblast Limited will post -0.05 EPS for the current year.

Institutional Investors Weigh In On Mesoblast

Several institutional investors and hedge funds have recently added to or reduced their stakes in MESO. GAMMA Investing LLC boosted its stake in Mesoblast by 14.1% in the 2nd quarter. GAMMA Investing LLC now owns 7,413 shares of the company’s stock valued at $100,000 after purchasing an additional 916 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Mesoblast in the 4th quarter valued at $32,000. Tobias Financial Advisors Inc. increased its position in Mesoblast by 38.3% during the 4th quarter. Tobias Financial Advisors Inc. now owns 13,828 shares of the company’s stock worth $249,000 after buying an additional 3,828 shares during the period. Royal Bank of Canada increased its position in Mesoblast by 22.5% during the 1st quarter. Royal Bank of Canada now owns 26,266 shares of the company’s stock worth $404,000 after buying an additional 4,827 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Mesoblast by 4.2% during the fourth quarter. Legal & General Group Plc now owns 679,023 shares of the company’s stock worth $12,237,000 after buying an additional 27,607 shares in the last quarter. 1.43% of the stock is owned by institutional investors.

About Mesoblast

Mesoblast Limited (NASDAQ: MESO) is a biotechnology company focused on developing and commercializing regenerative medicine products based on proprietary mesenchymal lineage stromal cells. The company’s cell therapies are designed to address serious inflammatory and immune-mediated conditions by potentially reducing inflammation, supporting tissue repair and modulating immune responses.

Mesoblast’s lead product, remestemcel-L, is marketed in the United States as Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.